SCHEMBL24377946

SCHEMBL24377946

Cc1ccc2c(c1)N(C(=O)CCl)CC(C(=O)Nc1ccccc1)O2

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TP53 P04637 4/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
GAA P10253 1/20 0.48
PKM P14618 1/20 0.48
MAPT P10636 3/20 0.48
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
POLB P06746 2/20 0.45
YAP1 P46937 1/20 0.44
TEAD4 Q15561 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24377947 0.87 YAP1 (0.49) TP53MEN1KMT2APKMLMNA
SCHEMBL29516124 0.83 TP53 (0.49) ALDH1A1SMN1; SMN2TP53MEN1KMT2A
SCHEMBL24378122 0.83 TP53 (0.49) ALDH1A1SMN1; SMN2TP53MEN1KMT2A
SCHEMBL26938741 0.83 TP53 (0.47) ALDH1A1SMN1; SMN2TP53MEN1KMT2A
SCHEMBL24378149 0.75 KMT2A (0.49) SMN1; SMN2TP53MEN1KMT2ALMNA
SCHEMBL29516475 0.75 KMT2A (0.49) SMN1; SMN2TP53MEN1KMT2ALMNA
SCHEMBL26939715 0.74 SIRT1 (0.47) ALDH1A1SMN1; SMN2TP53MEN1KMT2A
SCHEMBL26939793 0.74 KMT2A (0.40) ALDH1A1SMN1; SMN2TP53MEN1KMT2A
SCHEMBL26938749 0.73 POLB (0.44) SMN1; SMN2TP53MEN1KMT2AGAA
SCHEMBL24378019 0.72 SIRT1 (0.48) TP53GAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022087433-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-28 WO disclosed